{"id":68917,"date":"2026-04-09T17:36:17","date_gmt":"2026-04-09T12:06:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68917"},"modified":"2026-04-09T17:36:19","modified_gmt":"2026-04-09T12:06:19","slug":"cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/","title":{"rendered":"Cipla Share Price Target 2026: Analyst Forecast, Bull &amp; Bear Case"},"content":{"rendered":"<p>Cipla (NSE: CIPLA) is trading at Rs 1,420 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Cipla share price target stands at Rs 1,650-1,850 \u2014 implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term share price targets.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Current_Price_Overview\" title=\"Current Price Overview\">Current Price Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#About_Cipla\" title=\"About Cipla\">About Cipla<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Key_Catalysts_Driving_Cipla_Share_Price\" title=\"Key Catalysts Driving Cipla Share Price\">Key Catalysts Driving Cipla Share Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#1_US_Peptide_and_Complex_Generics_Pipeline\" title=\"1. US Peptide and Complex Generics Pipeline\">1. US Peptide and Complex Generics Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#2_Ciplas_US_complex_generics_pipeline_%E2%80%94_inhalers_injectables_and_peptides_%E2%80%94_is_the_most_advanced_among_Indian_mid-cap_pharma_Approvals_for_Advair_Diskus_fluticasonesalmeterol_Abraxane_biosimilar_paclitaxel_and_GLP-1_peptide_generics_are_multi-year_revenue_growth_drivers\" title=\"2. Cipla&#8217;s US complex generics pipeline \u2014 inhalers, injectables, and peptides \u2014 is the most advanced among Indian mid-cap pharma. Approvals for Advair Diskus (fluticasone\/salmeterol), Abraxane biosimilar (paclitaxel), and GLP-1 peptide generics are multi-year revenue growth drivers.\">2. Cipla&#8217;s US complex generics pipeline \u2014 inhalers, injectables, and peptides \u2014 is the most advanced among Indian mid-cap pharma. Approvals for Advair Diskus (fluticasone\/salmeterol), Abraxane biosimilar (paclitaxel), and GLP-1 peptide generics are multi-year revenue growth drivers.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#3_India_Respiratory_Leadership_%E2%80%94_Seretide_and_Combimist\" title=\"3. India Respiratory Leadership \u2014 Seretide and Combimist\">3. India Respiratory Leadership \u2014 Seretide and Combimist<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#4_Cipla_holds_the_leadership_position_in_Indias_branded_respiratory_drug_market_Seretide_fluticasone_and_Combimist_salbutamolipratropium_have_no_generic_threat_and_grow_at_12-15_annually\" title=\"4. Cipla holds the leadership position in India&#8217;s branded respiratory drug market. Seretide (fluticasone) and Combimist (salbutamol+ipratropium) have no generic threat and grow at 12-15% annually.\">4. Cipla holds the leadership position in India&#8217;s branded respiratory drug market. Seretide (fluticasone) and Combimist (salbutamol+ipratropium) have no generic threat and grow at 12-15% annually.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#5_South_Africa_Business_Recovery\" title=\"5. South Africa Business Recovery\">5. South Africa Business Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#6_Ciplas_South_Africa_business_pharmaceutical_distribution_and_branded_generics_is_recovering_as_rand_stabilises_and_private_healthcare_demand_grows_South_Africa_contributes_approximately_10_of_revenue\" title=\"6. Cipla&#8217;s South Africa business (pharmaceutical distribution and branded generics) is recovering as rand stabilises and private healthcare demand grows. South Africa contributes approximately 10% of revenue.\">6. Cipla&#8217;s South Africa business (pharmaceutical distribution and branded generics) is recovering as rand stabilises and private healthcare demand grows. South Africa contributes approximately 10% of revenue.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#7_Cipla_Foundation_%E2%80%94_Quality_and_Affordability_Brand\" title=\"7. Cipla Foundation \u2014 Quality and Affordability Brand\">7. Cipla Foundation \u2014 Quality and Affordability Brand<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#8_Ciplas_90-year_brand_in_India_%E2%80%94_built_on_making_AIDS_drugs_affordable_in_Sub-Saharan_Africa_%E2%80%94_commands_patient_and_doctor_trust_that_private_label_peers_cannot_replicate\" title=\"8. Cipla&#8217;s 90-year brand in India \u2014 built on making AIDS drugs affordable in Sub-Saharan Africa \u2014 commands patient and doctor trust that private label peers cannot replicate.\">8. Cipla&#8217;s 90-year brand in India \u2014 built on making AIDS drugs affordable in Sub-Saharan Africa \u2014 commands patient and doctor trust that private label peers cannot replicate.<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Key_Risks_to_Cipla_Share_Price\" title=\"Key Risks to Cipla Share Price\">Key Risks to Cipla Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Technical_Analysis_and_Support_Levels\" title=\"Technical Analysis and Support Levels\">Technical Analysis and Support Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Latest_Quarterly_Financial_Performance\" title=\"Latest Quarterly Financial Performance\">Latest Quarterly Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Institutional_Positioning_%E2%80%94_FII_DII_Promoter\" title=\"Institutional Positioning \u2014 FII, DII, Promoter\">Institutional Positioning \u2014 FII, DII, Promoter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Cipla_Share_Price_Target_2026\" title=\"Cipla Share Price Target 2026\">Cipla Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Short-Term_Target_3%E2%80%936_Months\" title=\"Short-Term Target (3\u20136 Months)\">Short-Term Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#12-Month_Analyst_Target\" title=\"12-Month Analyst Target\">12-Month Analyst Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Long-Term_Target_2027%E2%80%932028\" title=\"Long-Term Target (2027\u20132028)\">Long-Term Target (2027\u20132028)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#FAQs\" title=\"FAQs\">FAQs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Price_Overview\"><\/span><strong>Current Price Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>Current Market Price (CMP)<\/td><td>Rs 1,420<\/td><\/tr><tr><td>52-Week High<\/td><td>undefined<\/td><\/tr><tr><td>52-Week Low<\/td><td>undefined<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 1,14,600 Cr<\/td><\/tr><tr><td>P\/E Ratio<\/td><td>26x<\/td><\/tr><tr><td>12M Analyst Target<\/td><td>Rs 1,650-1,850<\/td><\/tr><tr><td>Bull Case<\/td><td>Rs 2,100<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 1,050<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Cipla\"><\/span><strong>About Cipla<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p><p>Cipla (NSE: CIPLA) is a leading listed company in the Pharma sector with a market capitalisation of Rs 1,14,600 Cr. The company operates across its core business segments and is well-positioned for the Indian economic growth cycle.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Catalysts_Driving_Cipla_Share_Price\"><\/span><strong>Key Catalysts Driving Cipla Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_Peptide_and_Complex_Generics_Pipeline\"><\/span><strong>1. US Peptide and Complex Generics Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Ciplas_US_complex_generics_pipeline_%E2%80%94_inhalers_injectables_and_peptides_%E2%80%94_is_the_most_advanced_among_Indian_mid-cap_pharma_Approvals_for_Advair_Diskus_fluticasonesalmeterol_Abraxane_biosimilar_paclitaxel_and_GLP-1_peptide_generics_are_multi-year_revenue_growth_drivers\"><\/span><strong>2. Cipla&#8217;s US complex generics pipeline \u2014 inhalers, injectables, and peptides \u2014 is the most advanced among Indian mid-cap pharma. Approvals for Advair Diskus (fluticasone\/salmeterol), Abraxane biosimilar (paclitaxel), and GLP-1 peptide generics are multi-year revenue growth drivers.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_India_Respiratory_Leadership_%E2%80%94_Seretide_and_Combimist\"><\/span><strong>3. India Respiratory Leadership \u2014 Seretide and Combimist<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Cipla_holds_the_leadership_position_in_Indias_branded_respiratory_drug_market_Seretide_fluticasone_and_Combimist_salbutamolipratropium_have_no_generic_threat_and_grow_at_12-15_annually\"><\/span><strong>4. Cipla holds the leadership position in India&#8217;s branded respiratory drug market. Seretide (fluticasone) and Combimist (salbutamol+ipratropium) have no generic threat and grow at 12-15% annually.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_South_Africa_Business_Recovery\"><\/span><strong>5. South Africa Business Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Ciplas_South_Africa_business_pharmaceutical_distribution_and_branded_generics_is_recovering_as_rand_stabilises_and_private_healthcare_demand_grows_South_Africa_contributes_approximately_10_of_revenue\"><\/span><strong>6. Cipla&#8217;s South Africa business (pharmaceutical distribution and branded generics) is recovering as rand stabilises and private healthcare demand grows. South Africa contributes approximately 10% of revenue.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_Cipla_Foundation_%E2%80%94_Quality_and_Affordability_Brand\"><\/span><strong>7. Cipla Foundation \u2014 Quality and Affordability Brand<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_Ciplas_90-year_brand_in_India_%E2%80%94_built_on_making_AIDS_drugs_affordable_in_Sub-Saharan_Africa_%E2%80%94_commands_patient_and_doctor_trust_that_private_label_peers_cannot_replicate\"><\/span><strong>8. Cipla&#8217;s 90-year brand in India \u2014 built on making AIDS drugs affordable in Sub-Saharan Africa \u2014 commands patient and doctor trust that private label peers cannot replicate.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_to_Cipla_Share_Price\"><\/span><strong>Key Risks to Cipla Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>US inhaler generic approval delays from FDA:&nbsp;<\/strong><\/p><p><strong>South Africa rand depreciation:&nbsp;<\/strong><\/p><p><strong>India branded margin compression:&nbsp;<\/strong><\/p><p><strong>Promoter holding below 40% creating governance questions:&nbsp;<\/strong><\/p><p>The 26% US reciprocal tariff on Indian goods \u2014 announced April 2, 2026 \u2014 has created a macro overhang affecting all Indian equities through FII outflows and earnings estimate revisions. Resolution of tariff uncertainty would be a meaningful positive catalyst for re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Analysis_and_Support_Levels\"><\/span><strong>Technical Analysis and Support Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Cipla is trading at Rs 1,420 vs. a 52-week range of undefined to undefined. Key technical support is at Rs 1,350-1,520. The 200-day moving average provides medium-term guidance for trend direction.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Cipla&#8217;s live price and get daily research insights.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Latest_Quarterly_Financial_Performance\"><\/span><strong>Latest Quarterly Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Key Metric<\/strong><\/td><td><strong>Latest Quarter<\/strong><\/td><td><strong>Year-Ago Quarter<\/strong><\/td><td><strong>YoY Change<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 7,073 Cr<\/td><td>Rs 6,429 Cr<\/td><td>+10.0%<\/td><\/tr><tr><td>Net Profit<\/td><td>Rs 1,571 Cr<\/td><td>Rs 1,242 Cr<\/td><td>+26.5%<\/td><\/tr><tr><td>EBITDA Margin<\/td><td>26.0%<\/td><td>24.2%<\/td><td>+180 bps<\/td><\/tr><tr><td>US Revenue<\/td><td>Rs 2,384 Cr<\/td><td>Rs 2,122 Cr<\/td><td>+12.3%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track Cipla&#8217;s live financials on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Positioning_%E2%80%94_FII_DII_Promoter\"><\/span><strong>Institutional Positioning \u2014 FII, DII, Promoter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Promoter holds 33.5%. FII holding is 20.4% and DII holds 16.8%. Institutional holding trends are a critical leading indicator for price direction. Rising FII holding typically precedes price recovery; declining FII signals ongoing caution. Track institutional flow changes on Univest Screener.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cipla_Share_Price_Target_2026\"><\/span><strong>Cipla Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Subscribe to Univest Pro for Premium Stock Research and F&amp;O Setups<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Short-term support and trading range: Rs 1,350-1,520. In the near term, the stock is likely to remain in this band pending clarity on Q4 FY26 results and FY27 guidance. Any macro positive from India-US tariff negotiations would accelerate a move toward the upper end of this range.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Target\"><\/span><strong>12-Month Analyst Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus for Cipla is Rs 1,650-1,850. The bear case \u2014 if FY27 guidance disappoints or macro headwinds intensify \u2014 is Rs 1,050. The bull case \u2014 on full earnings delivery and macro recovery \u2014 is Rs 2,100. These are analyst estimates based on publicly available data and may differ materially from actual price performance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%932028\"><\/span><strong>Long-Term Target (2027\u20132028)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>For 2027-2028, analysts project Cipla toward the Rs 2,200-2,600 range \u2014 assuming FY27 guidance delivery and normalisation of macro headwinds. Track live targets on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Cipla share price target for 2026 is Rs 1,650-1,850 based on analyst consensus. The bear case is Rs 1,050 and the bull case is Rs 2,100. At Rs 1,420, Cipla is trading at 26x P\/E with market cap of Rs 1,14,600 Cr. Whether this is a buy depends on your risk tolerance, investment horizon, and portfolio context. For more share price target analysis, visit&nbsp;<\/p><p><a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a><\/p><p><strong>Disclaimer: <\/strong>This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>Q1. What is Cipla share price target for 2026?<\/strong><\/p><p>The 12-month analyst consensus is Rs 1,650-1,850. Bull case: Rs 2,100. Bear case: Rs 1,050.<\/p><p><strong>Q2. Is Cipla a good buy at Rs 1,420?<\/strong><\/p><p>At 26x P\/E and Rs 1,420, Cipla offers potential recovery to Rs 1,650-1,850 over 12 months. Consult a SEBI-registered financial advisor before investing.<\/p><p><strong>Q3. What are the key risks for Cipla?<\/strong><\/p><p>Key risks include macro headwinds from US tariffs, sector-specific challenges, and any guidance miss in Q4 FY26 results. Monitor institutional holding trends on Univest Screener.<\/p><p><strong>Q4. What is Cipla long-term share price target?<\/strong><\/p><p>Long-term target for FY28 is Rs 2,200-2,600, contingent on sustained earnings delivery and macro recovery.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/coal-india-share-price-target-2026\">Coal India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/bharti-airtel-share-price-target\">Bharti Airtel Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/state-bank-of-india-share-price-target\">State Bank of India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/paytm-share-price-target\">Paytm Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Cipla (NSE: CIPLA) is trading at Rs 1,420 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Cipla share price target stands at Rs 1,650-1,850 \u2014 implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support<\/p>\n","protected":false},"author":27,"featured_media":68920,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-68917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"_edit_lock":["1775736461:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["73"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Cipla Share Price Target 2026: Analyst Forecast, Bull &amp; Bear Case"],"rank_math_description":["Cipla share price target 2026 \u2014 CMP Rs 1,420, consensus Rs 1,650-1,850. US peptide and complex generics, India respiratory leadership, South Africa recovery. Bull case Rs 2,100.\n"],"rank_math_focus_keyword":["Cipla Share Price Target"],"_thumbnail_id":["68920"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7691"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09173352\/Cipla-Share-Price-Target-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68917"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68917\/revisions"}],"predecessor-version":[{"id":68923,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68917\/revisions\/68923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68920"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}